 FREEHOLD, N.J., Dec. 30, 2020 GLOBE NEWSWIRE -- Avalon GloboCare Corp. NASDAQ: AVCO Avalon or The Company, a clinical-stage global developer of cell-based technologies and therapeutics, today announced an update on its partnership with the Institute for Synthetic Bioarchitectures at the University of Natural Resources and Life Sciences BOKU in Vienna, Austria. The collaboration brings together BOKUs S-layer nanotechnology with Avalons expertise in biomanufacturing, cell therapy engineering, and clinical development. 